Allosteric enhancement of the affinity of muscarinic receptors for their ligands offers a new way to influence cholinergic neurotransmission. The structure of the allosteric binding domain(s) and the features of agonists, antagonists and modulators which determine the occurrence of either positive or negative cooperativity require clarification. We tested interactions between allosteric modulators alcuronium, strychnine and brucine and eight antagonists at muscarinic receptors expressed in CHO cells. In experiments with unlabeled antagonists, all three modulators enhanced the affinity for 4-diphenylacetoxy-N-dimethylpiperidinium (4-DAMP) at the M2 receptors, and strychnine did so also at the M4 receptors. Positive interactions were also observed between alcuronium and L-hyoscyamine (M2) and scopolamine (M2), between strychnine and butylscopolamine (M4), L-hyoscyamine (M2 and M4) and scopolamine (M4), and between brucine and scopolamine (M2). Positive effects of alcuronium, strychnine and brucine on the affinity of the M2 receptors for 4-DAMP have been confirmed by direct measurements of the binding of [3H]-4-DAMP. A comparison of molecular models of several antagonists which are esters revealed that antagonists in which the distance between the N and the carboxyl C atoms corresponds to five chemical bonds are more likely to display positive cooperativity with alcuronium at the M2 receptors than the antagonists in which the N-carboxyl C distance corresponds to four chemical bonds.

Institute of Physiology Academy of Sciences of the Czech Republic Prague

Zobrazit více v PubMed

Mol Pharmacol. 1999 Dec;56(6):1245-53 PubMed

Eur J Pharmacol. 1995 Nov 30;291(3):427-30 PubMed

Br J Pharmacol. 1999 Jul;127(5):1240-6 PubMed

Mol Pharmacol. 1994 Apr;45(4):709-17 PubMed

Life Sci. 1997;60(13-14):1047-52 PubMed

Br J Pharmacol. 1998 Jul;124(6):1213-8 PubMed

Mol Pharmacol. 1997 Jul;52(1):172-9 PubMed

J Pharmacol Exp Ther. 1995 Jul;274(1):378-84 PubMed

J Pharmacol Exp Ther. 1991 Feb;256(2):727-33 PubMed

Mol Pharmacol. 2000 Jul;58(1):194-207 PubMed

Mol Pharmacol. 1998 Jul;54(1):139-45 PubMed

Mol Pharmacol. 1999 Apr;55(4):778-86 PubMed

Mol Pharmacol. 1995 Jan;47(1):88-98 PubMed

J Pharmacol Exp Ther. 1995 Sep;274(3):1077-83 PubMed

J Physiol Paris. 1998 Jun-Aug;92(3-4):241-3 PubMed

Phys Rev B Condens Matter. 1988 Jan 15;37(2):785-789 PubMed

Trends Pharmacol Sci. 1995 Jun;16(6):205-12 PubMed

Mol Pharmacol. 1995 Oct;48(4):696-702 PubMed

Biochem Pharmacol. 1973 Dec 1;22(23):3099-108 PubMed

Mol Pharmacol. 1989 Apr;35(4):469-76 PubMed

Mol Pharmacol. 1998 Mar;53(3):573-89 PubMed

J Pharmacol Exp Ther. 1986 Jan;236(1):219-23 PubMed

Mol Pharmacol. 1988 Feb;33(2):187-94 PubMed

Eur J Pharmacol. 1996 Jun 3;305(1-3):201-5 PubMed

Br J Pharmacol. 1976 Nov;58(3):323-31 PubMed

Mol Pharmacol. 1994 May;45(5):983-90 PubMed

Mol Pharmacol. 1989 Feb;35(2):173-6 PubMed

Clin Exp Pharmacol Physiol. 1998 Mar-Apr;25(3-4):185-94 PubMed

Mol Pharmacol. 1990 Nov;38(5):674-80 PubMed

Mol Pharmacol. 1995 Aug;48(2):362-78 PubMed

Br J Pharmacol. 1994 Dec;113(4):1529-37 PubMed

Mol Pharmacol. 1983 May;23(3):551-7 PubMed

Allosteric Modulation of Muscarinic Acetylcholine Receptors